BELLEVUE HEALTHCARE TRUST
PLC (the "Company")
LEGAL ENTITY IDENTIFIER ('LEI'):
213800HQ3J3H9YF2UI82
30 July 2024
ANNUAL
VOLUNTARY REDEMPTION OF ORDINARY SHARES
The Company operates a voluntary redemption
facility through which shareholders may request the redemption of
all or part of their holding of ordinary redeemable shares of 1p
each ("Ordinary Shares") for cash on the last business day in
November each year (or such other date as the Directors may
determine).
There is no
requirement for shareholders to take any action should they wish to
retain their Ordinary Shares.
As at close of business on 29 July 2024, the
Ordinary Share price was 146p and the net asset value ("NAV")
(including current period revenue) was 154.07p per Ordinary Share.
Therefore, the Ordinary Shares were trading at a 5.24% discount to
their NAV.
Given current market conditions and that the
Ordinary Shares continue to trade at a discount to NAV, it seems
prudent to assume that there may be material redemptions this year.
In view of this, and in order to enable the Company to discharge
its obligations under UK financial sanctions legislation, the
Company is again proposing changes to the redemption process and
timetable this year. The latest date for Redemptions Requests is
being brought forward to 11 October 2024, with the record date
being 2 September 2024. The Redemption Point is also being brought
forward to 5.00 p.m. on 22 November 2024.
This should have no material impact on our
long-standing investors. However, the longer gap between the final
date for Redemption Requests and the Redemption Point should allow
the Company to perform the appropriate checks (including issuing
section 793 notices, if required) of shareholders where the Company
cannot identify the ultimate beneficial owner (this can
particularly be the case for offshore nominee accounts). The
Directors will exercise their discretion not to redeem any Ordinary
Shares held by any member in default of supplying information
requested by the Company within the required timeframe or otherwise
in circumstances where such redemption might involve a breach of UK
financial sanctions legislation. Save in such circumstances, the
Directors are minded to approve all valid Redemption Requests
unless there are exceptional reasons why this would be contrary to
the interests of shareholders.
A redemption of Ordinary Shares may be subject
to income tax and/or capital gains tax. In particular,
private shareholders that sell their shares via the redemption
mechanism could find that they are subject to income tax on the
gains made on the redeemed shares rather than capital gains tax on
the sale of their shares in the market. However, individual
circumstances do vary, therefore shareholders who are in any doubt
about the redemption or the action that should be taken should seek
independent professional advice.
None of the Directors of the Company will be
redeeming any of their shares under the redemption
facility.
Shareholders submitting valid requests for the
redemption of Ordinary Shares and whose Redemption Requests are
accepted by the Directors will have their shares redeemed at the
Redemption Price.
The Directors may elect, at their absolute
discretion, to calculate the Redemption Price on either of the
following bases:
1. The Redemption Price shall
be equal to the Dealing Value per Ordinary Share calculated as at
the appropriate Valuation Point on the appropriate Redemption
Point; or
2. The Directors may elect to
calculate the Redemption Price by reference to the amount generated
upon the realisation of a Redemption Pool created for the purpose
of funding the redemption.
The Directors may alternatively arrange for all
or any of the Ordinary Shares the subject of valid Redemption
Requests to be sold in the market at not less than the Dealing
Value per Ordinary Share.
Shareholders wishing to request the redemption
of all or any of their certificated Ordinary Shares at the proposed
Redemption Point should deliver to the Company's Registrar a duly
completed Redemption Request form together with their share
certificate or for uncertificated Ordinary Shares a Transfer to
Escrow ("TTE") instruction in accordance with the timetable set out
below.
Redemption Request forms are available from the
Company's website:
https://www.bellevuehealthcaretrust.com/uk-en/private/investor-relations/legal-documents
or from the Company's Registrar, Link Group
(details below).
The relevant dates for the November 2024
Redemption Point are outlined below:
2 September 2024
11 October 2024
|
Date of record. The date from which
shareholders are required to be present on the Company's register
to be entitled to submit valid Redemption
Requests.
Latest date for receipt of Redemption Requests
and certificates for certificated shares.
|
3.00 pm on 11 October 2024
|
Latest date and time for TTE instructions for
uncertificated shares via CREST.
|
5.00 pm on 22 November 2024
|
The Redemption Point.
|
By 6 December 2024
|
If the Redemption Price is calculated by
reference to the Dealing Value per Ordinary Share, Company to
notify the number of shares being redeemed and the Redemption
Price, and dispatch redemption monies; or
If the Redemption Price is determined by reference to a Redemption
Pool, Company to notify the number of shares being redeemed.
Notification of Redemption Price and dispatch of redemption monies
to take place as soon as practicable thereafter.
|
By 20 December 2024
|
Balance certificates to be sent to
shareholders.
|
Further details of the redemption facility are
set out in the Company's Articles of Association, the Share
Issuance Programme prospectus issued in November 2018 and are also
available from the Company Secretary and the Company website. A
Q&A document will also be published on the Company website in
due course.
The Directors of the Company have discretion
over the operation of the redemption facility and the calculation
of the Redemption Price.
Defined terms
in the announcement have the same meaning as set out in the
Articles of Association, a copy of which may be obtained from the
Company Secretary.
Enquiries:
J.P.
Morgan Cazenove
|
William Simmonds, Rupert Budge
|
Telephone: +44 (0)20 3493 8000
|
|
NSM Funds (UK)
Limited
|
Brian Smith, Ciara McKillop
|
Telephone: +44 (0)20 3697 5770
|
|
Bellevue Asset
Management (UK) Ltd.
|
Mark Ghahramani
|
Telephone: +44 (0) 203 326 2981
|
If you have any further questions please call
Link Group on +44 (0) 371 664 0300. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside
the United Kingdom will be charged at the applicable international
rate. The helpline is open between 9.00 am - 5.30 pm, Monday to
Friday excluding public holidays in England and Wales. Please
note that Link Group cannot provide any financial, legal or tax
advice and calls may be recorded and monitored for security and
training purposes.